Treatment of Newly Diagnosed High Risk Acute Lymphoblastic Leukemia in Children
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
Treatment of pediatric acute lymphoblastic leukemia (ALL) has advanced and the overall
survival exceeds 80% nowadays. However the overall survival of high risk ALL remains 75-90%,
thus recent studies focus on treatment intensification according to the risk group. According
to the previous reports, we designed a multicenter prospective trial for pediatric ALL.
Phase:
Phase 2
Details
Lead Sponsor:
The Korean Society of Pediatric Hematology Oncology